Associate Director, Program Management
Flagship Pioneering, Inc.Cambridge, MA USA
Xenon PharmaceuticalsBoston, MAHybrid
75/100 · Strong. Based on age, reposts, pay, the company's hiring and ghost signals.
See the evidence behind this score.
Pro shows each part of the score, the reasons, the pay percentile and the listing history.
HirQ's ghost-risk estimate and company labels are automated opinions based on what we observe on employers' public job boards: how long a listing has been open, whether it was re-listed, wording in the description, and how often roles on that board close. They are not statements about an employer's intent, and a high-risk listing can still be a real opening. Figures are as of the date shown. How we measure
“Hybrid positions require a minimum of two onsite days per week.”
Employer-posted ranges for Project & Program Management roles in MA in the last 12 months (194 postings).
This job: $224k–$297k/yr
From Xenon Pharmaceuticals's careers page, checked Nov 22
Xenon Pharmaceuticals (NASDAQ:XENE https://www.nasdaq.com/market-activity/stocks/xene) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. We are looking for great people who thrive in a respectful, collaborative, inclusive, and productive culture to join the Xenon team.
We are advancing an exciting product pipeline https://xenon-pharma.com/pipeline to address indications with high unmet medical need, including epilepsy, depression and pain. Our Phase 3 azetukalner program represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. In March 2026, we announced positive topline data from our Phase 3 X-TOLE2 study of azetukalner in focal onset seizures (FOS), and we submitted a New Drug Application to the Food and Drug Administration in the third quarter of 2026. Our Phase 3 epilepsy program also includes a second FOS study, X-TOLE3, which would support regulatory submissions outside the U.S., and the X-ACKT study in primary generalized tonic-clonic seizures, which would support regulatory submissions for an additional epilepsy indication. We also have multiple Phase 3 azetukalner clinical trials underway in major depressive disorder (MDD) and bipolar depression (BPD), based on topline data from our Phase 2 X-NOVA clinical trial. In addition, we are proud of our strong heritage in human genetics, deep understanding of ion channel biology, and expertise in novel chemistries to enable potent, selective ion channel targeting. We continue to advance an early-stage pipeline of novel therapeutic candidates, including Phase 1 studies for XEN1701 and XEN1720 (targeting Nav1.7) and XEN1120 (targeting Kv7), which are being developed for pain. Backed by a strong balance sheet to support our growth plans, we continue to build a fully integrated, premier neuroscience company with strong discovery, clinical development, corporate, and commercial operations.
We are seeking a Director/Senior Director, Development Program Management, CMC to join our team. The Director/Senior Director, Development Program Management, CMC will provide strategic and operational project management leadership for CMC teams, with an initial focus on phase 1 and 2 compounds. This role will drive integrated planning, execution support, governance, and communication across multiple cross-functional programs and initiatives.
The successful candidate will partner closely with CMC and program stakeholders to translate strategy into clear, actionable execution plans; maintain high-quality project plans, dashboards, milestone trackers, risk and action logs; and ensure timely follow-up on key deliverables, decisions, dependencies, and risks. The role will also help strengthen project management practices through scalable tools, clear meeting governance, financial tracking, continuous improvement, and appropriate use of emerging technologies.
This position reports to the Senior Vice President, Portfolio and Alliance Management and will be based out of our Needham office. We will consider remote locations for exceptional candidates. The level of the position will be commensurate with the candidate’s education and industry experience. Hybrid positions require a minimum of two onsite days per week.
Our Total Rewards program includes base salary, target bonus, and stock options, as well as a full range of benefits including medical, dental, vision, short-& long-term disability, accidental death & dismemberment, and life insurance programs, Employee Assistance Program, travel insurance, and retirement savings programs with company matching contributions.
Xenon encourages time to rest and re-charge through vacation, personal days, sick days, and an end-of-year company shutdown. Xenon highly values employee development and has an expanding Training, Learning & Development program, including a Tuition Assistance program for advanced degrees.
Same role or field, nearby or remote, ranked by HirQ score.
Flagship Pioneering, Inc.Cambridge, MA USA
STRWoburn, MA
Real ChemistryBoston - Massachusetts; Carmel - Indiana; Chicago - Illinois; Lambertville - New Jersey; Remote - USAHybrid
FormlabsSomerville, MA
STRWoburn, MA
Director/Senior Director, Development Program Management, CMC
$224k–$297k/yr · HirQ 75